-

Monsanto Wins Third Circuit Court of Appeals Ruling in Schaffner v. Monsanto

Decision presents pathway to take preemption argument to U.S. Supreme Court

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, the Third Circuit Court of Appeals issued its ruling in Monsanto’s favor in the Schaffner v. Monsanto case, unanimously finding that the state-based failure-to-warn claims in this case are expressly preempted by the FIFRA statute.

This decision creates a circuit split with prior decisions of the Ninth and Eleventh Circuits on the central legal issues in the Roundup litigation and underscores the need for consistency on this important topic from a federal standpoint.

In response to the Schaffner v. Monsanto ruling, Monsanto issued the following statement:

“The Company is pleased with the unanimous decision from the Third Circuit holding that plaintiff’s state-based warning claims are expressly preempted by FIFRA. The Court concluded that ‘the alleged state-law duty to include the Cancer Warning on Roundup’s label imposes requirements that are different from those imposed under FIFRA, and that it is therefore preempted by FIFRA.”

“This decision on federal preemption, a cross-cutting issue in this litigation, creates a circuit split among the federal appellate courts and necessitates a review by the U.S. Supreme Court to settle this important issue of law. The Company is considering the impact of this ruling on other pending litigation and looks forward to presenting its arguments, as fully embraced by the Third Circuit, to the U.S. Supreme Court.”

“Bayer continues to stand fully behind its Roundup™ products – critical tools that farmers rely on to produce affordable food and feed the world – as the weight of scientific evidence and the conclusions of expert regulators worldwide continue to support the safety of glyphosate-based herbicides and that they are not carcinogenic.”

Contacts

Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Monsanto


Release Versions

Contacts

Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Monsanto

Monsanto Announces Roundup™ Class Settlement Agreement to Resolve Current and Future Claims

LEVERKUSEN, Germany & ST. LOUIS--(BUSINESS WIRE)--Today, Monsanto announced a proposed U.S. nationwide class settlement designed to resolve current and future Roundup™ claims alleging Non-Hodgkin lymphoma (NHL) injuries through a long-term claims program. Leading plaintiff law firms representing the class filed a motion today seeking preliminary approval of the settlement in the Circuit Court of the City of St. Louis, Missouri. The proposed class combined with Supreme Court review in the Durnel...

Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month

WHIPPANY, N.J.--(BUSINESS WIRE)--This American Heart Month, Bayer® Aspirin continues its mission to help people uncover the heart health risk factors they may not see with the launch of the Heart to Heart Bistro presented by Bayer® Aspirin. Created in partnership with Celebrity Chef, Jeff Mauro, the immersive dark dining experience invites Americans to confront one of the most dangerous and often overlooked barriers to heart health – denial – by bringing the unseen risk factors of cardiovascula...

Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared to placebo, both in combination with antiplatelet therapy. Asundexian significantly reduced ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p<.0001), in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase i...
Back to Newsroom